Volume 25, No 4, Apr 2015
ISSN: 1001-0602
EISSN: 1748-7838 2018
impact factor 17.848*
(Clarivate Analytics, 2019)
Volume 25 Issue 4, April 2015: 445-458 | Open Access
ORIGINAL ARTICLES
SMARCE1 suppresses EGFR expression and controls responses to MET and ALK inhibitors in lung cancer
Andreas I Papadakis1,*, Chong Sun2,*, Theo A Knijnenburg2,3, Yibo Xue1, Wipawadee Grernrum2, Michael Hölzel2,4, Wouter Nijkamp2, Lodewyk FA Wessels2, Roderick L Beijersbergen2, Rene Bernards2 and Sidong Huang1
1Department of Biochemistry, The Rosalind and Morris Goodman Cancer Centre, McGill University, Montreal, QC H3G 1Y6, Canada
2Division of Molecular Carcinogenesis, Cancer Systems Biology Centre and Cancer Genomics Centre, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands
3Institute for Systems Biology, 401 Terry Avenue North, Seattle, WA 98109-5234, USA
4Current address: Unit for RNA Biology, Department of Clinical Chemistry and Clinical Pharmacology, University of Bonn, 53105 Bonn, Germany
Correspondence: Sidong Huang, Tel: +1-514-398-4447; Rene Bernards, Tel: +31-20-512-1952( sidong.huang@mcgill.ca; r.bernards@nki.nl)
Recurrent inactivating mutations in components of SWI/SNF chromatin-remodeling complexes have been identified across cancer types, supporting their roles as tumor suppressors in modulating oncogenic signaling pathways. We report here that SMARCE1 loss induces EGFR expression and confers resistance to MET and ALK inhibitors in non-small cell lung cancers (NSCLCs). We found that SMARCE1 binds to regulatory regions of the EGFR locus and suppresses EGFR transcription in part through regulating expression of Polycomb Repressive Complex component CBX2. Addition of the EGFR inhibitor gefitinib restores the sensitivity of SMARCE1-knockdown cells to MET and ALK inhibitors in NSCLCs. Our findings link SMARCE1 to EGFR oncogenic signaling and suggest targeted treatment options for SMARCE1-deficient tumors.
10.1038/cr.2015.16
FULL TEXT | PDF
Browse 2155
